Peer review reports
From: Costs and benefits of bevacizumab vial sharing for the treatment of retinal diseases
Original Submission | ||
---|---|---|
29 Oct 2018 | Submitted | Original manuscript |
23 Jan 2019 | Reviewed | Reviewer Report - Yanmin Zhu |
31 Jan 2019 | Reviewed | Reviewer Report - Eric Finkelstein |
7 Mar 2019 | Author responded | Author comments - Savio Sodre |
Resubmission - Version 2 | ||
7 Mar 2019 | Submitted | Manuscript version 2 |
29 Mar 2019 | Reviewed | Reviewer Report - Yanmin Zhu |
29 Mar 2019 | Reviewed | Reviewer Report - Eric Finkelstein |
5 Jul 2019 | Author responded | Author comments - Savio Sodre |
Resubmission - Version 3 | ||
5 Jul 2019 | Submitted | Manuscript version 3 |
24 Jul 2019 | Reviewed | Reviewer Report - Eric Finkelstein |
8 Aug 2019 | Author responded | Author comments - Savio Sodre |
Resubmission - Version 4 | ||
8 Aug 2019 | Submitted | Manuscript version 4 |
10 Aug 2019 | Reviewed | Reviewer Report - Eric Finkelstein |
26 Aug 2019 | Author responded | Author comments - Savio Sodre |
Resubmission - Version 5 | ||
26 Aug 2019 | Submitted | Manuscript version 5 |
Publishing | ||
28 Aug 2019 | Editorially accepted | |
11 Sep 2019 | Article published | 10.1186/s12889-019-7562-y |